Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

PROphylaxis in NOn Major Orthopaedic Surgery (PRONOMOS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02401594
Recruitment Status : Terminated (Remaining outdated treatments and additional costs too high for new manufacturing)
First Posted : March 30, 2015
Last Update Posted : December 7, 2018
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Saint Etienne

Brief Summary:

PRONOMOS is an international multicentre, interventional, parallel, randomised, double-blind non-inferiority study comparing rivaroxaban 10mg od to an active comparator, enoxaparin 4000 UI od in 4040 valid subjects requiring orthopaedic surgery (except low risk such material removal foot surgery or hallux valgus without patient risk factor [6], and major orthopaedic surgeries for femoral neck and trochanteric fractures, THR, TKR)

Pre-randomization treatment with LMWH anticoagulant is allowed for a maximum duration of 24 hours. However, only a single pre-randomization dose of LMWH is allowed. After randomization, patients allocated to the rivaroxaban arm will receive rivaroxaban 10 mg once-daily started 6-10 hours provided haemostasis has been established after surgery or 24h hours after LMWH injection if needed for the intended treatment duration of 2 to 12 weeks based on medical judgment (according to immobilization). Patients allocated to the comparator arm will receive enoxaparin once daily for the same intended treatment duration. All patients will have a 30-day observational period after cessation of treatment.


Condition or disease Intervention/treatment Phase
Non-major Orthopaedic Surgery Drug: Rivaroxaban Drug: Enoxaparin Phase 3

Detailed Description:

Major orthopedic surgery (hip, knee replacements and hip fracture) represents only a small part of all orthopaedic surgery procedures. Procedures for trauma patients and orthopaedic lower limb surgery without trauma are much more frequent (tibia osteotomy, arthrodesis, ligament repair….).

The incidence of trauma patients requiring surgery and prolonged immobilisation is rising, mainly because of the increasing popularity of recreational sports. However, the epidemiology and prevention of VTE after such injuries have been poorly studied. The combination of limb surgery with or without trauma in orthopaedic surgery is responsible for an increase in venous thromboembolism (VTE). Usually, surgery of lower limb is considered as moderate or high risk for DVT with different duration related to immobilisation. For instance tibia osteotomy is at very high risk during at least 6 weeks and knee arthroscopy for ligament repair is at moderate risk during 10 days. However LMWH is recommended in both surgeries. Non-major orthopaedic surgery represents a major additional risk factor by itself; therefore such patients undergoing surgery deserve to receive VTE prophylaxis.

Rivaroxaban is a new oral anticoagulant developing a potent anti-Xa activity. In major orthopaedic surgery, it has shown to be more effective and as safe as LMWH (Enoxaparin 4000 IU once daily) in THR and TKR patients (RECORD program). Up to now, pending the limited number of surgical settings in which it has been developed in orthopaedic surgery, it is only approved for the prevention of venous thromboembolism (VTE) in THR and TKR procedures, which represent only 20% of all orthopaedic interventions. Non-major elective lower limb surgery and traumatology population is younger as compared to prosthetic orthopaedic surgery patients. Fewer VTE and cardiovascular events are to be feared. These patients receive quite often injectable thromboprophylaxis for a total duration lying between approximately 6 weeks to 3 months. In the one hand, the risk of major bleeding is low in this younger population. On the other hand, compliance and cost should be in favour of Rivaroxaban, because no injection and no platelets counts are needed.

The results of Xamos descriptive sub-analysis in non-elective (fracture related) orthopaedic surgery are consistent with the overall results of Xamos and are in favour of further investigations in this area. In this small subset of patients (n=790), the incidence of symptomatic thromboembolic events observed was low in patients treated with Xarelto and the overall frequency of treatment emergent major bleedings was low in both groups and serious adverse events occurred less frequently in patients treated with Xarelto. Therefore, collection of clinical data in this population is needed and awaited by many orthopaedic surgeons and anaesthetists in charge of VTE prophylaxis.

The population with femoral neck and trochanteric fracture is a specific one with different characteristics, elderly, frail and with a higher bleeding risk. This population will be excluded.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3608 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Multicentre, Randomised, Double-blind, Controlled, Phase IIIb Study to Assess the Efficacy and Safety of Rivaroxaban 10mg od Versus Enoxaparin 4000 UI for VTE PROphylaxis in NOn Major Orthopaedic Surgery
Actual Study Start Date : December 8, 2015
Actual Primary Completion Date : April 11, 2018
Actual Study Completion Date : April 16, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Group 1: Rivaroxaban treatment
Rivaroxaban active substance plus a placebo of enoxaparin
Drug: Rivaroxaban
10 mg once daily of Rivaroxaban active substance (10 mg tablet) plus a placebo syringe of enoxaparin 4000 UI once daily
Other Name: Group 1:

Active Comparator: Grouyp 2: Enoxaparine treatment
Enoxaparin active substance plus a placebo tablet of Rivaroxaban
Drug: Enoxaparin
A syringe of enoxaparin active substance 4000 UI once daily plus a placebo tablet of Rivaroxaban 10 mg.
Other Name: Group 2:




Primary Outcome Measures :
  1. Major VTE [ Time Frame: From date of randomization until the date of the end of the treatment period (up to 3 months maximum). ]

    composite of proximal DVT (asymptomatic and symptomatic) assessed by ultrasonography, symptomatic events (distal and proximal DVT, PE) and VTE related deaths.

    The treatment period ranges from 15 days to 3 months depending on the type of surgery



Secondary Outcome Measures :
  1. Major bleeding [ Time Frame: From date of randomization until the date of the end of the treatment period (up to 3 months maximum). ]

    bleeding event that meets at least one of the following criteria [5]:

    • fatal bleeding;
    • critical bleeding (intracranial, intraocular, intraspinal, pericardial, retroperitoneal);
    • clinically overt bleeding (at surgical or extrasurgical site) associated with a decrease in the haemoglobin level of more than 2 g/dL (20 g/l; 1.24 mmol/L) compared with the pre-randomization level;
    • clinically overt bleeding (at surgical or extrasurgical site) leading to transfusion of two or more units of whole blood or packed cells;
    • bleeding located at the surgical site and leading to re-operation or to any unusual medical intervention or procedure for relief (e.g. draining or puncture of an haematoma at the surgical site, transfer to an ICU or emergency room) The treatment period ranges from 15 days to 3 months depending on the type of surgery

  2. Clinically relevant non-major bleeding [ Time Frame: From date of randomization until the date of the end of the treatment period (up to 3 months maximum).. ]

    overt bleeding not meeting the criteria for major bleeding and corresponds to any bleeding necessitating medical intervention or a specific, unscheduled consultation or treatment discontinuation, or resulting in a deterioration of the subject's quality of life. Some examples of clinically significant bleeding are given below:

    • Epistaxis that lasts more than five minutes or recurrent or necessitates packing,
    • Spontaneous macroscopic haematuria or haematuria lasting more than 24 hours after instrumentation,
    • Gastrointestinal haemorrhage (melena or rectorrhagia),
    • Haemoptysis,
    • Subcutaneous haematoma > 100 cm². The treatment period ranges from 15 days to 3 months depending on the type of surgery

  3. Overt thrombocytopenia [ Time Frame: From date of randomization until the date of the end of the treatment period (up to 3 months maximum).. ]
    platelet count <100 giga/L or fall ≥ 50% of the platelet count as compared with the first post-operative count which will be done as local lab for all centres The treatment period ranges from 15 days to 3 months depending on the type of surgery

  4. Mortality [ Time Frame: From date of randomization until the date of the end of the treatment period (up to 3 months maximum).. ]
    All cause mortality The treatment period ranges from 15 days to 3 months depending on the type of surgery



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Signed and dated informed consent form,
  2. Age ≥ 18 years,
  3. Hospitalised for non-major orthopaedic surgery and requiring thromboprophylaxis according to the investigator's judgement on VTE risk such Achilles' repair, hip (except femoral neck and trochanteric fracture), knee, tibial plateau, femur (non femoral head), tibial and ankle fractures and tibial osteotomy, tibial transposition, arthrodesis of leg articulation, ligament repair of the knee or the ankle or any elective orthopaedic limb surgery requiring thromboprophylaxis).

Exclusion Criteria:

  1. Major orthopaedic surgery Hip and Knee replacement, femoral neck and trochanteric fractures, spine surgery,
  2. Low risk surgery without patient VTE risk: foot surgery (Hallux Valgus), material removal,
  3. Delay between hospitalisation and randomisation greater than two days,
  4. Women of childbearing potential not using a reliable contraceptive method throughout the study period (a list of reliable contraceptive methods is provided in the accompanying SPM),
  5. Women pregnant or breast-feeding during the study period,
  6. Body weight less than 50 kg (to avoid bleeding over risk) or over 120 kg,
  7. Long term treatment with VKA therapy or NOAC,
  8. Concomitant treatment with clopidogrel, prasugrel and ticagrelor,
  9. Platelet count < 100 Giga/L,
  10. Documented history of acquired or inherited bleeding disorder (e.g., von Willebrand's disease),
  11. Severe renal failure with calculated creatinine clearance (Cockcroft Formula) < 30 mL/min,
  12. Severe hepatic insufficiency with prothrombin time < 60% or liver impairment associated with coagulation disorders,
  13. History of thrombocytopenia,
  14. Any other current significant medical condition that might interfere with treatment evaluation according to the investigator's judgement,
  15. Known hypersensitivity or other severe reaction to any component of the investigational medicinal product(s),
  16. Participation in another clinical study involving an investigational medicinal product within 30 days prior to inclusion or concomitantly with this study,
  17. Active bleeding or contraindication to anticoagulant therapy
  18. Chronic alcoholic intoxication,
  19. Anticipated poor compliance of subject with study procedures

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02401594


Locations
Show Show 38 study locations
Sponsors and Collaborators
Centre Hospitalier Universitaire de Saint Etienne
Bayer
Investigators
Layout table for investigator information
Study Director: Marc SAMAMA, PhD Assistance Publique - Hôpitaux de Paris
Study Director: Nadia ROSENCHER, MD Assistance Publique - Hôpitaux de Paris
Principal Investigator: Patrick MISMETTI, PhD Centre Hospitalier Universitaire de Saint Etienne
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Centre Hospitalier Universitaire de Saint Etienne
ClinicalTrials.gov Identifier: NCT02401594    
Other Study ID Numbers: 1408143
2015-000981-70 ( EudraCT Number )
First Posted: March 30, 2015    Key Record Dates
Last Update Posted: December 7, 2018
Last Verified: December 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Centre Hospitalier Universitaire de Saint Etienne:
Non-major orthopaedic surgery
deep vein thrombosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Enoxaparin
Rivaroxaban
Factor Xa Inhibitors
Antithrombins
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anticoagulants
Fibrinolytic Agents
Fibrin Modulating Agents